Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Gastroenterology. 2022 Aug 2;163(6):1510–1521.e6. doi: 10.1053/j.gastro.2022.07.071

Figure 2.

Figure 2.

Symptom results for abdominal pain, bloating, tiredness, and non-stool composite which includes these symptoms and nausea. (A) Absolute severity for baseline and the 6-week GC treatment period for IMGX003 vs. placebo groups. Also shown are the magnitude of worsening for baseline vs. 6-week GC period. P-values are by ANCOVA for inter-group and paired t-test for intra-group results. (B) Mean change from baseline (% worsening) for three 2-week sequential GC treatment periods for IMGX003 vs. placebo. Also shown are the unpaired, 2-tailed, t-test p-values.